Diagnostic criteria for Huntington's disease based on natural history

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1335-1341

  Reilmann, Ralf ^a,b   Leavitt, Blair R ^c   Ross, Christopher A ^d  

^a George Huntington Institute   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Care; Chorea; Clinical trials; Diagnosis; Diagnostic criteria; Extrapyramidal; Huntington's disease; Manifest HD; Premanifest HD; Presymptomatic HD; Prodromal HD

Indexed keywords

CLASSIFICATION; COGNITION DISORDERS; COMPLICATION; DISEASE COURSE; GENETIC SCREENING; GENETICS; HUMAN; HUNTINGTON DISEASE; INTERNATIONAL CLASSIFICATION OF DISEASES; PROCEDURES; STANDARDS;

COGNITION DISORDERS; DISEASE PROGRESSION; GENETIC TESTING; HUMANS; HUNTINGTON DISEASE; INTERNATIONAL CLASSIFICATION OF DISEASES;

EID: 84907940340     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26011     Document Type: Article

References (39)

1. Hogarth, P, Kayson, E, Kieburtz, K, et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord 2005;20:293-297.
2. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
3. Biglan, KM, Zhang, Y, Long, JD, et al. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci. 2013;5:12. doi: 10.3389/fnagi.2013.00012
4. Paulsen, JS, Langbehn, DR, Stout, JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874-880.
5. Paulsen JS, Long JD, Johnson HJ, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci. 2014;6:78. doi: 10.3389/fnagi.2014.00078.
6. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
7. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
8. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
9. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
10. Aylward EH, Harrington DL, Mills JA, et al. Regional atrophy associated with cognitive and motor function in prodromal huntington disease. J Huntingtons Dis 2013;2:477-489.
11. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82:405-410.
12. Aylward EH, Liu D, Nopoulos PC, et al. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry 2012;71:822-828.
13. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
14. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75:2150-2160.
15. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010;75:1702-1710.
16. Scahill RI, Hobbs NZ, Say MJ, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2011;10.
17. Delmaire C, Dumas EM, Sharman MA, et al. The structural correlates of functional deficits in early huntington's disease. Hum Brain Mapp 2012;10.
18. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011;11:474-483.
19. Stout JC, Jones R, Labuschagne I, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 2012;83:687-694.
20. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10:204-216.
21. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. [see comments]. Cell 1993;72:971-983.
22. Massai L, Petricca L, Magnoni L, et al. Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells. BMC Biochem 2013;14:34. doi: 10.1186/1471-2091-14-34
23. Biglan KM, Ross CA, Langbehn, DR, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009;24:1763-1772.
24. Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011;25:1-14.
25. Harrington DL, Smith MM, Zhang Y, et al. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012;83:612-619.
26. Paulsen JS, Long JD . Onset of Huntington's disease: Can it be purely cognitive? Mov Disord 2014;29:1342-1350.
27. Duff K, Paulsen JS, Beglinger LJ, et al. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry 2007;62:1341-1346.
28. Epping EA, Mills JA, Beglinger LJ, et al. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J Psychiatr Res 2013;47:1423-1431.
29. Scaria J, Craufurd D. Clinical features of depression in huntington's disease: a cross sectional study comparing the clinical features of depression in patients with huntington's disease and in patients without huntington's disease. J Neurol Neurosurg Psychiatry 2014;85:e3-308883.
30. Ross CA, Pantelyat A, Kogan J, et al. Determinants of functional disability in Huntington's disease: Role of cognitive and motor dysfunction. Mov Disord 2014;29:1351-1358.
31. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group [published erratum appears in Neurology 2000;54:1712]. Neurology 2000;54:452-458.
32. Beglinger LJ, O'Rourke JJ, Wang C, et al. Earliest functional declines in Huntington disease. Psychiatry Res 2010;178:414-418.
33. Brossman B, Williams JK, Downing N, et al. Development of the Huntington disease work function scale. J Occup Environ Med 2012;54:1300-1308.
34. Sampaio C, Borowsky B, Reilmann R . Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. Mov Disord 2014;29:1419-1428.
35. de Boo G, Tibben A, Hermans J, et al. Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord 1998;13:96-99.
36. Bombard Y, Veenstra G, Friedman JM, et al. Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ 2009;338:b2175. doi: 10.1136/bmj.b2175
37. Bombard Y, Palin J, Friedman JM, et al. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2012;159B:217-226.
38. Erwin C, Williams JK, Juhl AR, et al. Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1081-1093.
39. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: What's in the pipeline. Mov Disord 2014;29:1434-1445.